GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » EV-to-FCF

Antengene (HKSE:06996) EV-to-FCF : -2.06 (As of Apr. 17, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Antengene EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Antengene's Enterprise Value is HK$896.66 Mil. Antengene's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-435.03 Mil. Therefore, Antengene's EV-to-FCF for today is -2.06.

The historical rank and industry rank for Antengene's EV-to-FCF or its related term are showing as below:

HKSE:06996' s EV-to-FCF Range Over the Past 10 Years
Min: -4.26   Med: 0.55   Max: 1.68
Current: -2.17

During the past 7 years, the highest EV-to-FCF of Antengene was 1.68. The lowest was -4.26. And the median was 0.55.

HKSE:06996's EV-to-FCF is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 2.1 vs HKSE:06996: -2.17

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-17), Antengene's stock price is HK$2.67. Antengene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.547. Therefore, Antengene's PE Ratio (TTM) for today is At Loss.


Antengene EV-to-FCF Historical Data

The historical data trend for Antengene's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene EV-to-FCF Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial -16.62 -4.23 -1.63 -0.18 -

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.63 - -0.18 - -

Competitive Comparison of Antengene's EV-to-FCF

For the Biotechnology subindustry, Antengene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Antengene's EV-to-FCF falls into.


;
;

Antengene EV-to-FCF Calculation

Antengene's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=896.661/-435.026
=-2.06

Antengene's current Enterprise Value is HK$896.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Antengene's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-435.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antengene  (HKSE:06996) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Antengene's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.67/-0.547
=At Loss

Antengene's share price for today is HK$2.67.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Antengene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.547.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Antengene EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Antengene's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene Business Description

Traded in Other Exchanges
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
Executives
Mei Jay 2201 Interest of corporation controlled by you
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines